HCW Biologics (NASDAQ:HCWB) reported quarterly losses of $(2.02) per share which missed the analyst consensus estimate of $1.58 by 227.85 percent. This is a 49.5 percent increase over losses of $(4.00) per share from the same period last year. The company reported quarterly sales of $15.606 million which beat the analyst consensus estimate of $7.000 million by 122.94 percent. This is a 3.56K percent increase over sales of $426.423 thousand the same period last year.